Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* First acute or subacute, well-defined neurological event consistent with demyelination (that is, optic neuritis confirmed by an ophthalmologist, spinal cord syndrome, brainstem/cerebellar syndromes)~* Onset of MS symptoms occurring within 90 days of randomization~* A screening MRI scan with 2 or more T2 lesions at least 3 millimeter (mm) in diameter that are characteristic of MS~Exclusion Criteria:~* Clinically relevant cardiovascular, hepatic, neurological, endocrine or other major systemic disease~* Significantly impaired bone marrow function~* Pregnancy or nursing~* Alcohol or drug abuse~* Use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate before enrollment~* Any known condition or circumstance that would prevent in the investigator's opinion compliance or completion of the study~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg (Type: PLACEBO_COMPARATOR): Core treatment period: Placebo matched to teriflunomide tablet once daily orally.~Extension treatment period: Re-randomized in 1:1 ratio to either teriflunomide 7 mg or 14 mg once daily orally.
- Teriflunomide 7 mg/7 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 7 mg tablet once daily orally.~Extension treatment period: Teriflunomide 7 mg tablet once daily orally.
- Teriflunomide 14 mg/14 mg (Type: EXPERIMENTAL): Core treatment period: Teriflunomide 14 mg tablet once daily orally.~Extension treatment period: Teriflunomide 14 mg tablet once daily orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).